Abstract

Lupus nephritis (LN) is a common and severe organ manifestation of systemic lupus erythematosus (SLE), and is associated with significant patient morbidity and mortality. Autoantibodies and aberrations in lymphocyte subsets have putative roles in the pathogenesis of SLE and LN, and might reflect disease activity and are amenable to immunosuppressive treatments. Anti-DNA is one of the well-studied autoantibodies, which correlates with disease activity and has direct nephritogenic effects on resident renal cells and various glomerular components. Other important autoantibodies in the pathogenesis of LN include anti-C1q, anti-α-actinin and anti-nucleosome antibodies. Changes in naive and memory B cells and plasma cells have been observed in SLE and LN patients. These B cell subsets exert diverse effects during pathogenesis of LN such as production of autoantibodies, secretion of proinflammatory and anti-inflammatory cytokines and presentation of auto-antigens to effector cells. Aberration of T lymphocytes, especially the T-helper subsets, is also highly pertinent in the development of LN. In this context, important T helper subsets include Th1, Th2, Th9, Th17, TReg and follicular T-helper cells. The growing knowledge on these autoantibodies and lymphocyte subset abnormalities will enhance our understanding of SLE and LN, and hence help devise better strategies for disease monitoring and treatment.

Highlights

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-systemic involvements

  • While mounting evidence had suggested the pathogenic significance of conventional autoantibodies, new target auto-antigens and their relevant autoantibodies have been continually identified to help understand the pathogenesis of Lupus nephritis (LN) as well as to expand our diagnostic and disease monitoring tools

  • Isles Lupus Activity Group (BILAG) scores) showed high circulating IL-23 levels [80]. These results suggested that a subset of LN patients exhibited Th17 phenotype that might affect response to treatment and could be evaluated as a biomarker for poor therapeutic response

Read more

Summary

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-systemic involvements. Proinflammatory and anti-inflammatory cytokines, autoantibodies, lymphocyte subset abnormalities as well as defects in the complement systems all have putative roles in the development of SLE. Among these factors, the contribution of autoantibodies and lymphocyte subset aberrations in the pathogenesis of renal disease in SLE cannot be over-emphasized. The contribution of autoantibodies and lymphocyte subset aberrations in the pathogenesis of renal disease in SLE cannot be over-emphasized In this context, there is a close link between the production of autoantibodies and the abnormalities in lymphocyte subpopulations.

The Role of Autoantibodies
Anti-dsDNA Antibody
Anti-C1q Autoantibody and Other Autoantibodies
The Role of B Lymphocytes and Its Subsets
The Role of T lymphocytes and Its Subsets
T-Helper Cells
Th17 and TReg
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call